Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer

Ramazan Yildiz; Mustafa Benekli; Metin Ozkan; Necati Alkis; Veli Berk; Mehmet Ali Kaplan; Aydin Ciltas; Halit Karaca; Ayse Gok Durnali; Ugur Coskun; Mustafa Dikilitas; Alper Sevinc; Faysal Dane; Tarkan Yetisyigit; Gamze Gokoz Dogu; Suleyman Buyukberber

首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer

【24h】

Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer

机译：贝伐单抗每4周与每2周联合双周FOLFIRI在转移性结直肠癌中的疗效相同

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

The efficacy and tolerability of bevacizumab every 2 or 4 weeks using the same dosage in combination with biweekly FOLFIRI were retrospectively evaluated in metastatic colorectal cancer (mCRC) patients in the first-line and second-line therapy.

机译：回顾性评估一线和二线治疗中转移性结直肠癌（mCRC）患者每2或4周使用相同剂量贝伐单抗联合双周FOLFIRI的疗效和耐受性。

著录项

来源
《Journal of Cancer Research and Clinical Oncology》 |2012年第11期|p.1845-1852|共8页
作者
Ramazan Yildiz; Mustafa Benekli; Metin Ozkan; Necati Alkis; Veli Berk; Mehmet Ali Kaplan; Aydin Ciltas; Halit Karaca; Ayse Gok Durnali; Ugur Coskun; Mustafa Dikilitas; Alper Sevinc; Faysal Dane; Tarkan Yetisyigit; Gamze Gokoz Dogu; Suleyman Buyukberber;
展开▼
作者单位

Departments of Medical Oncology, Gazi University Faculty of Medicine, Besevler, 06500, Ankara, Turkey;

Departments of Medical Oncology, Gazi University Faculty of Medicine, Besevler, 06500, Ankara, Turkey;

Erciyes University Faculty of Medicine, Kayseri, Turkey;

Dr. Abdurrahman Yurtaslan Education and Research Hospital, Ankara, Turkey;

Erciyes University Faculty of Medicine, Kayseri, Turkey;

Dicle University Faculty of Medicine, Diyarbakir, Turkey;

Departments of Medical Oncology, Gazi University Faculty of Medicine, Besevler, 06500, Ankara, Turkey;

Erciyes University Faculty of Medicine, Kayseri, Turkey;

Dr. Abdurrahman Yurtaslan Education and Research Hospital, Ankara, Turkey;

Departments of Medical Oncology, Gazi University Faculty of Medicine, Besevler, 06500, Ankara, Turkey;

Erciyes University Faculty of Medicine, Kayseri, Turkey;

Gaziantep University Faculty of Medicine, Gaziantep, Turkey;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Bevacizumab; Metastatic colorectal cancer; FOLFIRI;

机译：贝伐单抗;转移性结直肠癌;FOLFIRI;

相似文献

外文文献
中文文献
专利

1. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer [J] . YildizR., BenekliM., OzkanM., Journal of Cancer Research and Clinical Oncology . 2012,第11期

机译：贝伐单抗每4周与每2周联合双周FOLFIRI在转移性结直肠癌中的疗效相同
2. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis [J] . Wei Xu, Meng Kuang, Yang Gong, OncoTargets and therapy . 2016,第2期

机译：FOLFOXIRI±贝伐单抗组合与FOLFIRI±贝伐单抗组合作为不可切除的转移性结直肠癌一线治疗的生存获益和安全性：一项荟萃分析
3. 6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study) [J] . M.Ducreux, A.Adenis, J.P.Pignon, European Journal of Cancer Supplements . 2009,第2期

机译：6084基于贝伐单抗的联合方案对转移性结直肠癌患者的疗效和安全性：贝伐单抗+ FOLFIRI与贝伐单抗+ XELIRI的随机II期研究的最终结果（FNCLCC ACCORD 13/0503研究）
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Enhancement of Gemcitabine and Paclitaxel Uptake and Retention in Metastatic Cancer Cells: A Novel Targeted Combination Delivery Approach to Eliminate Breast Cancer in Blood and Lymph [D] . Yu, Jesse. 2020

机译：吉西他滨和紫杉醇吸收的增强和转移性癌细胞的保留：一种小型靶向组合递送方法，消除血液和淋巴中的乳腺癌
6. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis [O] . Wei Xu, Meng Kuang, Yang Gong, 2016

机译：FOLFOXIRI±贝伐单抗组合与FOLFIRI±贝伐单抗组合作为不可切除的转移性结直肠癌一线治疗的生存获益和安全性：一项荟萃分析
7. PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE [O] . Gyldmark M, Aultman R, Siebert U, 2009

机译：在转移性结肠直肠癌患者中，贝伐珠单抗加福利普利对福利普利的一线联合治疗的PCN69成本效益：

Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅